Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings

Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD) diabetic macular edema (DME) and retinal vein occlusion (RVO).
Kodiak presented the data at the Angiogenesis, Exudation, and Degeneration 2021 Annual Meeting.
Data showed that two-thirds of patients in each disease cohort achieved a 6-month or longer treatment-free interval at the one-year mark – 66% of wet AMD patients, 69% of DME patients, and 66% of RVO patients.
78% of wet AMD patients and 84% of DME patients were on a 4-month or longer interval at Year 1, as were 75% of RVO patients. 54% of wet AMD patients required only one retreatment, and 50% of DME patients required no retreatment in Year 1.
The DAZZLE wet AMD study is fully recruited with an expected data read-out in early 2022, and GLEAM and GLIMMER studies in DME and BEACON study in RVO are actively recruiting.
Price Action: KOD stock closed 2.2% down at $157.03 on Friday.